AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06224205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
Study NCT05684055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line antihypertensive single-pill combination (SPC)
Description: In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
Study NCT05684055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized counselling and referral to the closest health facility
Description: In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
Study NCT05682625 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04817670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 120 mg
Description: Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study NCT04817670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 360 mg
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally.
Study NCT04817670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 240 mg
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study NCT04817670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study NCT04817670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TID
Description: Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study NCT05702463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab twice daily for 7 days
Description: Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
Study NCT05702463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 40Mg Chew Tab twice daily for 7 days
Description: Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
Study NCT05702463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg EC Tab once daily for 7 days
Description: Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
Study NCT05642741 — intervention group
Intervention type: OTHER
Intervention: Response to medical and research questionnaires
Description: Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
Study NCT06330805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT06330805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV
Study NCT06330805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given injection
Study NCT06330805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06330805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo functional fitness tests
Study NCT06330805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study NCT06639594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
Study NCT05007405 — intervention group
Intervention type: OTHER
Intervention: Groups/Cohortes
Description: Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer):~1. A general questionnaire, with collection of general health history and exposure data~2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits.~3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety.
Study NCT05403112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone ring with open sinus lifting
Description: All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Fasting blood sampling.
Description: In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Saliva collection and nasal or nasopharyngeal swab
Description: On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Urine samples
Description: During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Hair and a tonenail (or hand nail) sampling
Description: During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Nasal microbiota
Description: Nasal or nasopharyngeal swab
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Measurements
Description: In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes.
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Neuroimaging
Description: A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed
Study NCT05322343 — intervention group
Intervention type: OTHER
Intervention: Medical visit
Description: For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
Study NCT05916339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication
Description: Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)
Study NCT05916339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Description: If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex
Study NCT05478850 — intervention group
Intervention type: PROCEDURE
Intervention: radiotherapy under anesthesia
Description: Body temperature change will be investigated before the procedure and during recovery in Radiotherapy patients who need anesthesia due to childhood malignancies.
Study NCT04309734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-777
Description: Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.
Study NCT04309734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, as one or two placebo capsules, depending on the arm.
Study NCT04309734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
Study NCT06220435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiotherapy regimen.
Description: * Prostate tumor(s): 49 Gray (Gy)/7 fractions~* Prostate gland: 42.7 Gy/7 fractions~* Elective lymph nodes: 29.4 Gy/7 fractions~* Seminal vesicles: 31.15 Gy/7 fractions
Study NCT05632042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification (exercise and control of diet)
Description: erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
Study NCT05506384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaps Preventions Therapy
Description: The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.
Study NCT05506384 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
Study NCT06458283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hiybrid simulation
Description: The intervention group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by a high-reality simulator accompanied by a scenario, and the control group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by an adult standard patient care model.
Study NCT06458283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control grup
Description: low fidelity simulator
Study NCT04968990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiation (PBRT)
Description: The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
Study NCT04968990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DD-4A Chemotherapy Regimen
Description: Patients will receive standard of care chemotherapy based on diagnosis and stage.
Study NCT04968990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Surgical Resection
Description: Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
Study NCT04968990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
Study NCT04968990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Nephrectomy
Description: Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
Study NCT05682508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education group
Description: Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable.
Study NCT06433791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate-Meglumine
Description: Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection
Study NCT04629508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: itacitinb Immediate Release (IR) will be dosed orally twice a day
Study NCT06561295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Later Morning Timing of Spontaneous Breathing Trials
Description: Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
Study NCT05298579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga exercises
Description: Yoga-based exercise training includes a warm-up and cool-down period for beginners
Study NCT05298579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercises
Description: Yoga-based exercise training includes a warm-up and cool-down period for beginners
Study NCT04328714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Description: To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume.
Study NCT05774353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaire
Description: Patients included in the study will complete an online questionnaire (LimeSurvey).
Study NCT06166654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: 1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
Study NCT06166654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone 2.5 MG
Description: 2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
Study NCT06166654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double-placebo
Description: This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
Study NCT05890833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The risk of falls
Description: Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
Study NCT06329830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: 7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles
Study NCT06329830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib abiraterone acetate
Description: Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg
Study NCT06329830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally twice per day
Study NCT05940103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Description: AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
Study NCT05777486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TikTok Ads - With Food
Description: TikTok posts from influencers promoting food.
Study NCT05777486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TikTok Ads - Without Food
Description: TikTok posts from influencers who are not promoting food.
Study NCT04786743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endoscopic intervention
Description: performing endoscopy
Study NCT04786743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: endoscopic intervention
Description: performing endoscopy
Study NCT05467007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire® Respiratory Panel 2.1-EZ
Description: BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
Study NCT06047561 — intervention group
Intervention type: RADIATION
Intervention: PET-CT
Description: PET combined with CT or MRI
Study NCT06444659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Physical Activity Classes
Description: The intervention group received a 6 months adaptive physical activity intervention; the control group, on the other hand, continued their original regular physical activity programme for the same period of time and maintained their original lifestyle habits.